AHR Stock Forecast & Price Target

American Healthcare REIT is positioned to compound value through strong internal growth in its RIDEA segments, with ISHC generating about 60% of NOI and SHOP rising to 22% of NOI as of 2Q26 while still benefiting from occupancy and pricing tailwinds. Its fundamentals are further reinforced by accretive capital deployment, as roughly $2.4B of closed and awarded investments, plus a substantial pipeline, should support estimated nFFO growth of 27% in '26 and 15% in '27. The balance sheet also looks supportive, with net debt-to-EBITDA at 2.5x as of 2Q26 and significant liquidity that can fund future acquisitions while preserving flexibility in a higher-rate environment.

American Healthcare REIT is exposed to a structurally weak risk-reward setup, as its 4.7% implied cap rate sits 150 bps below the healthcare sector average of 6.2% and 260 bps below the REITs overall average of 7.3%, leaving little margin for error. Its outlook is further pressured by heavy tenant concentration, with over half of NOI coming from Trilogy and roughly half of Trilogy NOI tied to skilled nursing beds, making earnings highly sensitive to reimbursement changes, Medicaid cuts, labor shortages, and regulatory shifts. Although the company cited nearly 6% sequential SSNOI growth in ISHC and 5% in SHOP, the market still faces elevated operational volatility, availability and cost of capital risk, and potential slowdown from the SNF backdrop.